DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer Phase II Results

We know that prostate cancer is a heterogeneous disease, but most of our treatments are not based on the different molecular stratification exhibited by the disease. One of the differences we do recognize in the cancer is that some of the tumors have genetic DNA-repair defects. There has been evidence that in those cancers exhibiting these types of defects, a possible treatment is poly(adenosine diphosphate [ADP]–ribose) polymerase (PARP) inhibition with the investigation treatment olaparib. Researchers conducted a phase 2 trial in which men with metastatic, castration-resistant prostate cancer (mCRPC) were treated with olaparib tablets at a dose of 400 mg [...]

Can PARP Inhibitors Like Olaparib Provide Life Extension For Men With Early Disease?

The drugs called PARP inhibitors have been increasing discussed in the world of prostate cancer. There is every good reason to believe that we will continue to hear more about them and for certain select men with prostate cancer they will probably become a part of their treatment. In a recent paper published in the New England Journal of Medicine there are detailed data about the activity of one of these PARP inhibitors, olaparib, in the treatment of select men with metastatic, castration-resistant prostate cancer (mCRPC). In the paper by Mateo et al., (DNA-Repair Defects and Olaparib in Metastatic Prostate [...]

Olaparib – Effective for Certain Genetic Metastatic Prostate Cancer Strains

I have talked a lot about our need to take the next step in clinical care, understanding the best sequencing of our drugs. Since we have a number of new drugs to treat advanced prostate cancer we now need to better understand which drugs should be used in which men as well as their proper sequencing. To do this we need to understand the genetic differences that our cancers have from each other. Cancer is a genetic disease and what we refer to, as prostate cancer is not one distinct disease, but it is many different diseases. To better sequence [...]

Understanding How Personalized Medicine Is Developed By Way Of A Real Situation – Olaparib

It is common knowledge that men with metastatic castration-resistant prostate cancer (CRPC) don’t all have the same disease. There are many different types or flavors of prostate cancer. These differences are involved in the genetic structure of the cancer cell its self. Some prostate cancers have mutations in the DNA repair genes (genes whose job is to repair other gene mutations). It has been shown that prostate cancer that have these mutations are more likely to respond to the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib. (Currently olaparib is FDA approved for certain types of advanced ovarian cancers.) In the recently evaluated [...]